The porcine coronary model of in-stent restenosis: current status in the era of drug-eluting stents.
Drug-eluting stents are revolutionizing interventional cardiology. Sirolimus-eluting stents are in widespread clinical use, associated with well-documented remarkably low restenosis rates, and a number of other agents appear promising in clinical trials. These human studies have been preceded by numerous animal studies, foremost among them the pig coronary model of in-stent restenosis (ISR). The histologic response to porcine coronary stenting was described over a decade ago. Porcine stenting studies now provide examinations not only of histology, but also mechanisms of action, toxicity, and biocompatibility. This review therefore examines the current status of this porcine coronary model of ISR. Contemporary methods of pig coronary stenting are discussed. The morphometric, cellular, and molecular analyses of the responses to stent injury are then described. Finally, recent pig coronary drug-eluting stent studies are examined, with a discussion of their advantages, limitations, and possible future modifications.
Lowe
Harry C
HC
Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. h.lowe@unsw.edu.au
Schwartz
Robert S
RS
Mac Neill
Briain D
BD
Jang
Ik-Kyung
IK
Hayase
Motoya
M
Rogers
Campbell
C
Oesterle
Stephen N
SN
D000818:Animals; D023903:Coronary Restenosis / Q000517:prevention & control*; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D013552:Swine
D007166:Immunosuppressive Agents; D020123:Sirolimus